In summary, our data for the first time reveal that miR-181a-5p promotes osteosarcoma progression via PTEN/AKT pathway and that miR-181a-5p is a promising therapeutic target to treat osteosarcoma. The gene discussed is AKT1; the disease is osteosarcoma.